WO2006125105A3 - Methods and compositions for treating and diagnosing multiple sclerosis - Google Patents

Methods and compositions for treating and diagnosing multiple sclerosis Download PDF

Info

Publication number
WO2006125105A3
WO2006125105A3 PCT/US2006/019292 US2006019292W WO2006125105A3 WO 2006125105 A3 WO2006125105 A3 WO 2006125105A3 US 2006019292 W US2006019292 W US 2006019292W WO 2006125105 A3 WO2006125105 A3 WO 2006125105A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
treating
multiple sclerosis
diagnosing multiple
Prior art date
Application number
PCT/US2006/019292
Other languages
French (fr)
Other versions
WO2006125105A2 (en
Inventor
Scott Jelinsky
Suzana Marusic
John Leonard
Original Assignee
Wyeth Corp
Scott Jelinsky
Suzana Marusic
John Leonard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Scott Jelinsky, Suzana Marusic, John Leonard filed Critical Wyeth Corp
Publication of WO2006125105A2 publication Critical patent/WO2006125105A2/en
Publication of WO2006125105A3 publication Critical patent/WO2006125105A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for treating and diagnosing inflammatory, autoimmune and/or neurologic disorders, e.g., multiple sclerosis, are provided. In addition, methods for identifying agents that can be used in such therapeutic and diagnostic methods are disclosed.
PCT/US2006/019292 2005-05-19 2006-05-18 Methods and compositions for treating and diagnosing multiple sclerosis WO2006125105A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68273505P 2005-05-19 2005-05-19
US60/682,735 2005-05-19

Publications (2)

Publication Number Publication Date
WO2006125105A2 WO2006125105A2 (en) 2006-11-23
WO2006125105A3 true WO2006125105A3 (en) 2007-05-24

Family

ID=37432153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019292 WO2006125105A2 (en) 2005-05-19 2006-05-18 Methods and compositions for treating and diagnosing multiple sclerosis

Country Status (1)

Country Link
WO (1) WO2006125105A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058153A1 (en) * 1998-05-08 1999-11-18 Brigham & Women's Hospital Methods of diagnosing and modulating autoimmunity
WO2002021129A1 (en) * 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. Method of monitoring the effect of cathepsin s inhibitors
WO2003020287A2 (en) * 2001-08-30 2003-03-13 Novartis Ag Methods for the treatment of chronic pain anc compositions therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058153A1 (en) * 1998-05-08 1999-11-18 Brigham & Women's Hospital Methods of diagnosing and modulating autoimmunity
WO2002021129A1 (en) * 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. Method of monitoring the effect of cathepsin s inhibitors
WO2003020287A2 (en) * 2001-08-30 2003-03-13 Novartis Ag Methods for the treatment of chronic pain anc compositions therefor

Also Published As

Publication number Publication date
WO2006125105A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2005046434A8 (en) Compositions and methods for diagnosing and treating mental disorders
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
EP1696929A4 (en) Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
PL2481756T3 (en) Compositions and methods for diagnosing and treating cancer
WO2007112288A3 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2006096490A8 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
AP2005003474A0 (en) Compositions and methods for increasing telomeraseactivity.
EP1827389A4 (en) Sustained-release nanoparticle compositions and methods for using the same
IL178661A0 (en) Topical methadone compositions and methods for using the same
WO2007019376A3 (en) Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
HK1098383A1 (en) Compositions and methods for treating coagulation related disorders
WO2003061593A3 (en) Novel targeted compositions for diagnostic and therapeutic use
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2007073554A3 (en) Block copolymer particles
WO2006068987A3 (en) Uses of il-23 antagonists in the treatment of diabetes mellitus
WO2006116609A3 (en) Methods for treating lower motor neuron diseases and compositions for the same
EP2564864B8 (en) FGF2-related methods for diagnosing and treating depression
SI2327792T1 (en) Methods and compositions for detecting auto-immune disorders
HK1096298A1 (en) Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
EP1722771A4 (en) Compositions and methods for preventing or treating an inflammatory response
WO2007028151A3 (en) Surgical devices and related methods thereof
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
WO2006091930A3 (en) Methods and compounds for promoting vessel regression

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06770593

Country of ref document: EP

Kind code of ref document: A2